140 related articles for article (PubMed ID: 24780466)
1. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?
Schepers E; Speer T; Bode-Böger SM; Fliser D; Kielstein JT
Semin Nephrol; 2014 Mar; 34(2):97-105. PubMed ID: 24780466
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?
Kielstein JT; Fliser D; Veldink H
Semin Dial; 2009; 22(4):346-50. PubMed ID: 19708979
[TBL] [Abstract][Full Text] [Related]
3. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA).
Tain YL; Hsu CN
Toxins (Basel); 2017 Mar; 9(3):. PubMed ID: 28272322
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach.
Oliva-Damaso E; Oliva-Damaso N; Rodriguez-Esparragon F; Payan J; Baamonde-Laborda E; Gonzalez-Cabrera F; Santana-Estupiñan R; Rodriguez-Perez JC
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357472
[TBL] [Abstract][Full Text] [Related]
5. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
[TBL] [Abstract][Full Text] [Related]
6. The past, presence and future of ADMA in nephrology.
Kielstein JT; Fliser D
Nephrol Ther; 2007 Apr; 3(2):47-54. PubMed ID: 17452300
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
Kielstein JT; Zoccali C
Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
[TBL] [Abstract][Full Text] [Related]
8. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.
Hov GG; Aasarød KI; Sagen E; Åsberg A
Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044
[TBL] [Abstract][Full Text] [Related]
9. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantitative determination of N(G),N(G)-dimethyl-L-arginine or asymmetric dimethylarginine and related pathway's metabolites in biological fluids by ultrahigh-performance liquid chromatography/electrospray ionization-tandem mass spectrometry.
Di Gangi IM; Chiandetti L; Gucciardi A; Moret V; Naturale M; Giordano G
Anal Chim Acta; 2010 Sep; 677(2):140-8. PubMed ID: 20837180
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
Kielstein JT; Zoccali C
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):609-15. PubMed ID: 18941355
[TBL] [Abstract][Full Text] [Related]
12. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
13. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
15. HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application.
Ivanova M; Artusi C; Boffa GM; Zaninotto M; Plebani M
Clin Chim Acta; 2010 Nov; 411(21-22):1632-6. PubMed ID: 20542018
[TBL] [Abstract][Full Text] [Related]
16. [ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology].
Sela BA
Harefuah; 2005 Sep; 144(9):655-9, 675, 674. PubMed ID: 16218539
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
[TBL] [Abstract][Full Text] [Related]
18. Role of asymmetrical dimethylarginine in the progression of renal disease.
Raptis V; Kapoulas S; Grekas D
Nephrology (Carlton); 2013 Jan; 18(1):11-21. PubMed ID: 23016674
[TBL] [Abstract][Full Text] [Related]
19. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
20. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C
Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
